Financial Guidance and Company Overview

Antares Portfolio Offers Diversified Commercial and Platform Royalty Revenues PROPRIETARY PRODUCTS Commercial XYOSTEDⓇ, TLANDOTM, and NOCDURNAⓇ Development ATRS-1901, ATRS-1902, and ATRS- 1903 ROYALTY BUSINESS Commercial Generic EpiPenⓇ, Generic Forsteo® (Ex-U.S.), Sumatriptan, and Makena Development Teva (Generic ForteoⓇ (U.S.)), Idorsia Pharmaceuticals (selatogrel) and Pfizer (undisclosed) XYOSTED DC54436-275-00 €75.m $184M A Liquid 2021 REVENUE (+23% VS 2020) $36.6M CASH FROM OPERATIONS FOR 12 MONTHS ENDING 12/31/21 Halozyme For the twelve months ended December 31, 2021, as proprietary products represent 43% of total revenue 5

View entire presentation